Can trials be completed sooner...biotech might have some answers in the long run with genomic assistance....BD
Add a few U.S. attorneys to the long list of folks looking into what happened with that failed trial of Vytorin, the cholesterol drug from Merck and Schering-Plough.
There was a flurry of action in the early months of the year, as the company reported that the drug failed to show a benefit over a generic alone in a long-awaited study. Most of the questions had to do with why it took the companies nearly two years after the trial was completed to report the results.
0 comments :
Post a Comment